Monitoring monocyte HLA-DR expression and CD4 + T lymphocyte count in dexamethasone-treated severe COVID-19 patients
Authors' conclusion
By using standardized immunomonitoring tools available in clinical practice, it is possible to identify a subgroup of patients at high risk of mortality at the end of a 10-day dexamethasone treatment.
Study context
- Population
- Adult critically ill COVID-19 patients under dexamethasone with ICU LOS of at least 10 days
- Participants
- 176 participants
- Exposure
- Low vs normal mHLA-DR and CD4+ T lymphocyte count at day 10 after ICU admission
- Outcome
- 28-day ICU mortality
- Follow-up
- 28 days
Main finding
As reported in the abstract
Association of day-10 biomarkers with 28-day ICU mortality · day 10
Decreased mHLA-DR and low CD4
60%
Adjusted hazard ratio (CI)P value
Low mHLA-DRmultivariate analysis including age, comorbidities or pre-existing immunosuppression
2.86(1.30–6.32)
P = 0.009Low CD4
2.10(1.09–4.04)
P = 0.027Decreased mHLA-DR and low CD4
4.83(1.72–13.57)
P = 0.001Observational data: associations, not effects.
Original publication
Monitoring monocyte HLA-DR expression and CD4 + T lymphocyte count in dexamethasone-treated severe COVID-19 patients. Ann Intensive Care. Published 18 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →